Somewhere right now, a bag of red cells is quietly aging.
It left a donor's arm weeks ago. It has been spun, filtered, chilled to refrigerator temperature, and parked in a blood bank, waiting. The clock on it reads 42 days, the outer limit a unit of red blood cells is allowed to live before it gets discarded. And every one of those days, oxygen has been gnawing at it - stiffening the cells, leaking their contents, dimming the very thing it exists to deliver: oxygen to a patient who needs it.
Hemanext exists because of that bag. The company, headquartered off Hayden Avenue in Lexington with a team of roughly three dozen people, builds a system that changes what happens inside it. Not the donor, not the patient, not the 42-day calendar - the air. Hemanext pulls the oxygen out and keeps it out, and then watches the storage lesion slow down.
The whole business plan fits in one word. The word is oxygen. The trick is taking it away.
— The Hemanext thesis, abbreviatedStored blood doesn't fail loudly. It fails slowly.
Transfusion is one of medicine's oldest reliable moves. It is also, oddly, one of its least reengineered. For decades, donated red cells have been stored in oxygen-permeable plastic bags with an additive solution, and for decades clinicians have known that older units are not quite as good as fresh ones. The cells grow rigid. They shed potassium and free hemoglobin. Their ability to unload oxygen where it is needed degrades. Researchers have a tidy clinical name for this: the storage lesion.
The inconvenient part is that the lesion is largely driven by oxidative damage - and the storage bag is full of oxygen the whole time. The blood, in effect, slowly rusts. Most of the supply chain treated this as a fact of life, the unavoidable tax you pay for keeping blood on a shelf. Hemanext treated it as a design flaw.
Everyone agreed older blood was worse. Almost no one was changing the thing the blood was sitting in.
— On the status quo Hemanext set out to disturb
A 2008 idea, an NIH grant, and a very long fuse.
Hemanext was founded in 2008 by Martin Cannon, backed early on by a grant from the National Institutes of Health. It spent its first stretch of life under a different name, New Health Sciences, before rebranding to Hemanext in 2017 - a rare case of a company picking a name that actually tells you what it does to blood.
The bet was patient to the point of stubbornness. Reengineering a blood product is not a software sprint; it is clinical studies, regulatory submissions, manufacturing, and the slow accumulation of evidence that hospitals and blood banks will accept. The founding wager was that if you controlled oxygen from the moment of processing all the way through day 42, you could deliver a measurably better unit without asking the blood bank to change its calendar or its workflow.
Fifteen years from idea to FDA authorization. Nobody builds a blood company if they are in a hurry.
— The unglamorous timeline of medtechIn September 2023, Cannon retired and handed the company to Andrew Dunham, formerly its chief technology officer - the person who had been engineering the oxygen out of the equation moving into the seat that has to sell it to the world.
A company in milestones
Hemanext ONE: same shelf, less rust.
The product is called Hemanext ONE, and it does something deceptively boring. During processing, it strips oxygen and carbon dioxide out of a unit of leukocyte-reduced red blood cells. Then it keeps the unit hypoxic - low-oxygen - for the duration of refrigerated storage, up to 42 days. The cells stay more flexible, their membranes more intact, their metabolism more stable.
What it pointedly does not do is reinvent the blood bank. The storage window is still 42 days. The workflow still fits the rhythm of a transfusion service. The difference is invisible to everyone except the cells, which is exactly the point. Hemanext ONE earned FDA authorization originally through the De Novo route - the pathway reserved for genuinely new device categories - and later a 510(k) clearance expanding which red cell products it can handle, from whole-blood-derived to apheresis-derived units. It is also CE marked in Europe.
Hemanext ONE limits oxygen, the fuel for oxidative damage, providing a higher quality blood product.
— Hemanext, on what the system actually doesHow Hemanext funded a 15-year science project
Bars scaled for comparison, not to a single axis. Figures are public reported approximations and span multiple rounds and grants.
Evidence is the only currency that matters here.
In medtech, a clever idea earns you exactly nothing until the data shows up. Hemanext ONE ran multicenter validation studies across four countries - Italy, Germany, Norway and Switzerland - and the units processed with the system consistently met or exceeded regulatory quality standards. It became the first blood processing and storage system to receive the AABB Standards-Compliant seal, which is the blood banking establishment's way of nodding in approval.
Then there is the clinic. Hemanext launched the αO2-PRBCThal trial, evaluating its hypoxic red cells in patients with transfusion-dependent thalassemia - people who receive transfusions for life and whose bodies are an unforgiving test of blood quality. The trial measures whether Hemanext-processed blood can support these patients without raising transfusion burden, hemolysis, or metabolic disturbance. Partners along the way have included the blood services organization Vitalant and the Thalassaemia International Federation.
Four countries ran the studies independently and arrived at the same conclusion. That is the kind of agreement that moves a blood bank.
— On the multicenter validation resultsBetter blood for the people who can't choose theirs.
Hemanext frames its mission plainly: improve the quality, safety, efficacy, and cost of transfusion therapy so that every transfusion can deliver a better outcome. The patients with the most at stake are the chronic ones - thalassemia, sickle cell disease, myelodysplastic syndromes - who receive transfusions repeatedly over years, accumulating the consequences of whatever quality their blood happened to have. For them, a marginally better unit, multiplied across a lifetime, is not marginal.
It is a mission with an unusual humility built in. Hemanext is not trying to be visible to patients. Success looks like a system humming away in the background of a blood bank, doing its work on the air, while nobody in the hospital has to think about it at all.
The best outcome for Hemanext is that you never learn its name - and the transfusion just works a little better.
— On a deliberately invisible kind of impactFive things worth knowing
- Hemanext spent its early life as "New Health Sciences" before adopting a name that actually advertises blood.
- The entire scientific pitch reduces to one element on the periodic table - oxygen - and the decision to remove it.
- Hypoxic storage still runs the standard 42 days; the innovation is in the air, not the calendar.
- Its validation work happened in four countries simultaneously, which is a lot of travel for a bag of red cells.
- From a 2008 NIH-backed idea to FDA authorization took more than 15 years - a reminder that blood moves slower than software.
Back to that bag.
Return to where we started: a unit of red cells, weeks old, sitting in a blood bank, waiting for a patient. In the old story, oxygen has been working against it the entire time, and the best anyone could do was use it before day 42 and hope fresher was available for the patients who needed it most.
In Hemanext's version, the oxygen was removed at the start and kept away through every one of those days. The bag still reads 42 days. The blood bank still runs its normal routine. But the cells inside are less stiff, less leaky, closer to the day they were donated. When that bag finally reaches an arm - a thalassemia patient on their hundredth transfusion, a trauma case on a surgical table - it arrives carrying less of the damage that storage used to guarantee.
That is the entire company, sitting in a single bag. Hemanext didn't make blood younger. It just stopped letting the air make it older.